ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)

Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

GlaxoSmithKline Agrees To Pay States $14M To Settle Charges That It Blocked Generic Version Of Paxil

GlaxoSmithKline on Tuesday agreed to pay $14 million to states to settle allegations that the company blocked generic versions of its antidepressant Paxil, causing state health programs to pay higher prices, the AP/Philadelphia Inquirer reports. Attorneys general of 49 states and Washington, D.C., filed suit alleging that GSK used frivolous lawsuits against generic drug makers, leading to automatic extensions of Paxil's patent (Robrish, AP/Philadelphia Inquirer, 3/29). The states' suit, filed in federal court in Philadelphia on Monday, sought to recover excess Paxil expenditures by Medicaid between 1997 and 2003. The suit claimed that GSK's original patent for Paxil, which was due to expire in 1997, had always been questionable. GSK acquired rights to the drug in 1980, and the patent was due to expire in 1992. However, GSK obtained a new patent in 1980 on a slightly different version of the drug that contained an extra water molecule, which gave the company exclusive rights to sell the drug for five additional years. The attorneys general argued that when that period expired, GSK developed a dozen new patent applications covering slightly different versions of Paxil's active ingredient, which triggered an automatic hold on FDA approvals of generic versions. In addition, GSK filed a suit against generic manufacturers that were attempting to market a cheaper version of Paxil, a move that the attorneys general called "sham litigation." GSK later withdrew three patent applications, allowing a generic version to reach the market in September 2003. GSK recently agreed to pay $165 million to settle two similar suits regarding Paxil's patent extensions, one brought by pharmacies and another by consumers and private insurers (Tansey, San Francisco Chronicle, 3/29). West Virginia was the only state that did not participate in the attorneys general's suit. Comments
Missouri Attorney General Jay Nixon (D) said, "GSK used the courts to hold onto a monopoly for a popular drug, and the end result was that consumers -- including Medicaid -- paid more than they should have." He added, "This settlement demonstrates that we won't allow pharmaceutical companies to be rewarded for actions that penalize consumers" (AP/Philadelphia Inquirer, 3/29). California Attorney General Bill Lockyer (D) said, "This multibillion-dollar drug company unjustly enriched itself at the expense of health insurers, consumers fighting depression and, in this case, taxpayers." Lockyer added, "GSK fraudulently obtained patents; used those patents to maintain an unlawful monopoly; denied purchasers access to cheaper, generic versions of Paxil; and burdened the courts with meritless lawsuits to keep its ill-gotten profits flowing" (San Francisco Chronicle, 3/29). Gaile Renegar, GSK spokesperson, said the company denies any wrongdoing and is not admitting liability in making the settlement. She said, "We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation" (Philadelphia Inquirer, 3/29).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Paxil CR.





GlaxoSmithKline de acord sã plãteascã membre $ 14m de rezolvare a unor taxe care Aceasta versiune a blocat Generic Paxil - GlaxoSmithKline Agrees To Pay States $14M To Settle Charges That It Blocked Generic Version Of Paxil - articole medicale engleza - startsanatate